Genome scan of clot lysis time and its association with thrombosis in a protein C-deficient kindred

Journal of Thrombosis and Haemostasis

Volumn 9, Issue 7, 2011, Pages 1383-1390

  Meltzer, M E ^a,b   Hasstedt, S J ^c   Vossen, C Y ^a,b   Callas, P W ^d   De Groot, Ph G ^a   Rosendaal, F R ^b   Lisman, T ^a,e   Bovill, E G ^d  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Fibrinolysis; Protein C deficiency; QTL; TAFI; Venous thrombosis

Indexed keywords

PROTEIN C; PROTHROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; WARFARIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; BLOOD CLOT LYSIS TIME; BLOOD CLOTTING TEST; CHILD; CHROMOSOME 11; CHROMOSOME 13; FEMALE; FIBRINOLYSIS; GENE LINKAGE DISEQUILIBRIUM; GENE MUTATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HERITABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; QUANTITATIVE TRAIT LOCUS; RISK FACTOR; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; VEIN THROMBOSIS;

BLOOD COAGULATION TESTS; CARBOXYPEPTIDASE U; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 13; FAMILY; FIBRINOLYSIS; GENETIC LINKAGE; GENOME, HUMAN; HUMANS; MUTATION; PROTEIN C DEFICIENCY; PROTHROMBIN; QUANTITATIVE TRAIT LOCI; THROMBOSIS;

EID: 79959855819     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2011.04343.x     Document Type: Article

References (37)

1. Guimaraes AH, de Bruijne EL, Lisman T, Dippel DW, Deckers JW, Poldermans D, Rijken DC, Leebeek FWG. Hypofibrinolysis is a risk factor for arterial thrombosis at young age. Br J Haematol 2009; 145: 115-20.
2. Lisman T, de Groot PG, Meijers JCM, Rosendaal FR. Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. Blood 2005; 105: 1102-5.
3. Meltzer ME, Doggen CJM, de Groot PhG, Rosendaal FR, Lisman T. Reduced plasma fibrinolytic capacity as a potential risk factor for a first myocardial infarction in young men. Br J Haematol 2009; 145: 121-7.
4. Meltzer ME, Lisman T, Doggen CJM, de Groot PG, Rosendaal FR. Synergistic effects of hypofibrinolysis and genetic and acquired risk factors on the risk of a first venous thrombosis. PLoS Med 2008; 5: e97.
5. Meltzer ME, Lisman T, de Groot PG, Meijers JC, le Cessie S, Doggen CJ, Rosendaal FR. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. Blood 2010; 116: 113-21.
6. Lisman T, Leebeek FWG, Mosnier LO, Bouma BN, Meijers JCM, Janssen HL, Nieuwenhuis HK, de Groot PG. Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology 2001; 121: 131-9.
7. Wichers IM, Tanck MW, Meijers JCM, Lisman T, Reitsma PH, Rosendaal FR, Buller HR, Middeldorp S. Assessment of coagulation and fibrinolysis in families with unexplained thrombophilia. Thromb Haemost 2009; 101: 465-70.
8. Colucci M, Binetti BM, Tripodi A, Chantarangkul V, Semeraro N. Hyperprothrombinemia associated with prothrombin G20210A mutation inhibits plasma fibrinolysis through a TAFI-mediated mechanism. Blood 2004; 103: 2157-61.
9. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999; 353: 1167-73.
10. Bovill EG, Bauer KA, Dickerman JD, Callas P, West B. The clinical spectrum of heterozygous protein C deficiency in a large New England kindred. Blood 1989; 73: 712-17.
11. Hasstedt SJ, Bezemer ID, Callas PW, Vossen CY, Trotman W, Hebbel RP, Demers C, Rosendaal FR, Bovill EG. Cell adhesion molecule 1: a novel risk factor for venous thrombosis. Blood 2009; 114: 3084-91.
12. Bovill EG, Hasstedt SJ, Callas PW, Valliere JE, Scott BT, Bauer KA, Long GL. The G20210A prothrombin polymorphism is not associated with increased thromboembolic risk in a large protein C deficient kindred. Thromb Haemost 2000; 83: 366-70.
13. Weber JL, Broman KW. Genotyping for human whole-genome scans: past, present, and future. Adv Genet 2001; 42: 77-96.
14. Hasstedt SJ, Scott BT, Callas PW, Vossen CY, Rosendaal FR, Long GL, Bovill EG. Genome scan of venous thrombosis in a pedigree with protein C deficiency. J Thromb Haemost 2004; 2: 868-73.
15. Heath SC. Markov chain Monte Carlo segregation and linkage analysis for oligogenic models. Am J Hum Genet 1997; 61: 748-60.
16. Frere C, Tregouet DA, Morange PE, Saut N, Kouassi D, Juhan-Vague I, Tiret L, Alessi MC. Fine mapping of quantitative trait nucleotides underlying thrombin-activatable fibrinolysis inhibitor antigen levels by a transethnic study. Blood 2006; 108: 1562-8.
17. Elston RC, Stewart J. A general model for the genetic analysis of pedigree data. Hum Hered 1971; 21: 523-42.
18. Hasstedt SJ. jPAP: document-driven software for genetic analysis. Genet Epidemiol 2005; 29; 255. [Abstract]
19. Almasy L, Blangero J. Multipoint quantitative-trait linkage analysis in general pedigrees. Am J Hum Genet 1998; 62: 1198-211.
20. Fukudome K, Esmon CT. Identification, cloning, and regulation of a novel endothelial cell protein C/activated protein C receptor. J Biol Chem 1994; 269: 26486-91.
21. van Hylckama Vlieg A, Callas PW, Cushman M, Bertina RM, Rosendaal FR. Inter-relation of coagulation factors and d-dimer levels in healthy individuals. J Thromb Haemost 2003; 1: 516-22.
22. Vossen CY, Callas PW, Hasstedt SJ, Long GL, Rosendaal FR, Bovill EG. A genetic basis for the interrelation of coagulation factors. J Thromb Haemost 2007; 5: 1930-5.
23. Warren DM, Cole SA, Dyer TD, Soria JM, Souto JC, Fontcuberta J, Blangero J, Maccluer JW, Almasy L. A locus on chromosome 13 influences levels of TAFI antigen in healthy Mexican Americans. Hum Biol 2006; 78: 329-39.
24. Sabater-Lleal M, Buil A, Souto JC, Alamsy L, Borrell M, Lathrop M, Blangero J, Fontcuberta J, Soria JM. A genome-wide exploration suggests an oligogenic model of inheritance for the TAFI activity and its antigen levels. Hum Genet 2008; 124: 81-8.
25. Ladenvall C, Gils A, Jood K, Blomstrand C, Declerck PJ, Jern C. Thrombin activatable fibrinolysis inhibitor activation peptide shows association with all major subtypes of ischemic stroke and with TAFI gene variation. Arterioscler Thromb Vasc Biol 2007; 27: 955-62.
26. Huisman LG, van Griensven JM, Kluft C. On the role of C1-inhibitor as inhibitor of tissue-type plasminogen activator in human plasma. Thromb Haemost 1995; 73: 466-71.
27. Schreiber AD, Kaplan AP, Austen KF. Plasma inhibitors of the components of the fibrinolytic pathway in man. J Clin Invest 1973; 52: 1394-401.
28. Anteby EY, Greenfield C, Natanson-Yaron S, Goldman-Wohl D, Hamani Y, Khudyak V, Ariel I, Yagel S. Vascular endothelial growth factor, epidermal growth factor and fibroblast growth factor-4 and -10 stimulate trophoblast plasminogen activator system and metalloproteinase-9. Mol Hum Reprod 2004; 10: 229-35.
29. Olofsson B, Korpelainen E, Pepper MS, Mandriota SJ, Aase K, Kumar V, Gunji Y, Jeltsch MM, Shibuya M, Alitalo K, Eriksson U. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc Natl Acad Sci USA 1998; 95: 11709-14.
30. Kojima S, Muramatsu H, Amanuma H, Muramatsu T. Midkine enhances fibrinolytic activity of bovine endothelial cells. J Biol Chem 1995; 270: 9590-6.
31. Medcalf RL, Kruithof EK, Schleuning WD. Plasminogen activator inhibitor 1 and 2 are tumor necrosis factor/cachectin-responsive genes. J Exp Med 1988; 168: 751-9.
32. Hong MG, Bennet AM, de Faire U, Prince JA. Phenotype selection for detecting variable genes: a survey of cardiovascular quantitative traits and TNF locus polymorphism. Eur J Hum Genet 2007; 15: 685-93.
33. Betel D, Wilson M, Gabow A, Marks DS, Sander C. The microRNA.org resource: targets and expression. Nucleic Acids Res 2008; 36: D149-53.
34. Falconer M. Introduction to Quantitative Genetics. Harlow: Longman, 1996.
35. Carter AM, Cymbalista CM, Spector TD, Grant PJ. Heritability of clot formation, morphology, and lysis: the EuroCLOT study. Arterioscler Thromb Vasc Biol 2007; 27: 2783-9.
36. Williams FM, Carter AM, Kato B, Falchi M, Bathum L, Surdulescu G, Kyvik KO, Palotie A, Spector TD, Grant PJ. Identification of quantitative trait loci for fibrin clot phenotypes: the EuroCLOT study. Arterioscler Thromb Vasc Biol 2009; 29: 600-5.
37. Zeegers M, Rijsdijk F, Sham P. Adjusting for covariates in variance components QTL linkage analysis. Behav Genet 2004; 34: 127-33.